


# HPTN 083-01 - Safety, Tolerability and Acceptability of Long-Acting Cabotegravir for the Prevention of HIV among Adolescent Males - A sub-study of HPTN 083

Atlas Open Report - June 13, 2023

Visit Cutoff Date: June 13, 2023

### Figure O1 - Cumulative Enrollment - All Sites

Total Enrolled: 9 Enrollment Target: 55 Enrollment Needed: 46



Source: SCHARP (Anusha) - /trials/hptn/p083-01/analysis/atlas/code/open/g\_accrual.sas, SAS Version 9.4 (13JUN2023,13:06)

HPTN 083-01 - Safety, Tolerability and Acceptability of Long-Acting Cabotegravir for the Prevention of HIV among Adolescent Males - A sub-study of HPTN 083  
 Atlas Open Report - June 13, 2023  
 Visit Cutoff Date: June 13, 2023

Figure 1a. Cumulative Enrollment - Boston

Total Enrolled: 4 Enrollment Target: 14 Enrollment Needed: 10




Figure 1b. Cumulative Enrollment - Chicago - AYAR

Total Enrolled: 3 Enrollment Target: 14 Enrollment Needed: 11




Figure 1c. Cumulative Enrollment - Aurora

Total Enrolled: 1 Enrollment Target: 14 Enrollment Needed: 13




Figure 1d. Cumulative Enrollment - Memphis

Total Enrolled: 1 Enrollment Target: 13 Enrollment Needed: 12

